1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merit Medical said on July 7, 2025 that Martha Aronson will become President and CEO effective October 3, 2025, succeeding Fred Lampropoulos, who will remain Chairman. The company also reported preliminary, unaudited second-quarter revenue of approximately $380 million to $384 million, up about 12% to 14% from the prior-year quarter, with constant currency growth of about 11% to 13%. The revenue figures are not audited and may change when full results are released on July 30, 2025.
Martha Aronson to succeed Fred Lampropoulos as CEO effective October 3, 2025; Lampropoulos remains Chairman
Aronson offer includes a $1,000,000 base salary, a $250,000 signing bonus and a target annual bonus of 100% of salary
Initial equity award with a target grant-date fair value of $5,500,000, plus a $4,125,000 award on commencement of employment
Preliminary Q2 revenue of approximately $380 million to $384 million versus $338.0 million a year earlier; full results due after market close July 30, 2025
Central Garden & Pet said on July 11, 2025 that it raised its fiscal 2025 non-GAAP earnings per share outlook to approximately $2.60, citing margin expansion from its Cost and Simplicity initiatives and a favorable product mix. The filing does not state the prior outlook, so the size of the increase cannot be determined from this document. The company also cautioned that its fourth quarter is seasonally small and that consumer demand remains uncertain.
Fiscal 2025 non-GAAP EPS outlook raised to approximately $2.60 for the fiscal year ending September 28, 2025
Company expects fiscal 2025 capital expenditures of approximately $60 million
Outlook excludes the potential impact of further tariff changes and any acquisitions, divestitures, or restructuring
Additional details to be provided on the fiscal 2025 third-quarter earnings call on August 6, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.